Some good stuff to think on:
I was reading about "other mmj pharma related companies" striving for FDA approval and expansion of patents.
This relates well for OWCP;
SAN DIEGO, CA--(Marketwired - November 16, 2016) - Medical Marijuana, Inc. (OTC PINK: MJNA) announced today that its major investment AXIM® Biotechnologies, Inc. (AXIM® Biotech) (AXIM), a world leader in hemp cannabinoid research and development, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 9,433,601, a patent that claims the use of all cannabinoids in cannabinoid-containing controlled-release chewing gum products.
A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from the application, filed in April 2015. This patent covers the inclusion of all cannabinoids (both natural and synthetic) in a chewing gum delivery system, including Tetrahydrocannabinol (THC), all of which may be incorporated in the Company's chewing gum products.
This new patent is an extension of AXIM® Biotech's patent for chewing gum as delivery methods for cannabidiol (Chewing Gum Compositions Comprising Cannabinoids). Prior to this new allowance, Patent 9,023,322 only claimed gum products as a delivery mechanism for cannabidiol (CBD)
"We congratulate the AXIM team on receiving this new patent, another major milestone in the Company's continued efforts to research new solutions using cannabinoid-based drugs," said Dr. Stuart Titus, CEO of Medical Marijuana, Inc.
"This patent will enable AXIM to include any of the at least 85 different cannabinoid compounds found in the cannabis plant, including CBD and THC, into its multiple cannabinoid controlled-release chewing gum products,"
<-- You see? This is only Gum, their patent for gum delivery system was EXPANDED to include any of at least 85 different cannabinoid compounds found in the cannabis plant
AXIM® Biotech developed the patents it now owns for chewing gum as a delivery method for cannabinoids into two separate products. Its CBD-only Canchew® gum is marketed and is legal to purchase wherever CBD hemp oil products are sold. AXIM® Biotech holds the exclusive rights to market and distribute CanChew® Gum globally. CanChew® is a botanical hemp-derived CBD chewing gum with a unique oral mucosal absorbance delivery system.
In addition, AXIM® will start clinical trials for its combination CBD/THC gum, MedChew® Rx, for the treatment of pain and spasticity associated with multiple sclerosis.
the estimated market size for MedChew® Rx is $4.8 billion USD. MedChew® Rx is on track to be fully registered by the EMA and FDA.
A gum delivery system with an estimated market size of $4.8 BILLION DOLLARS!
Also see they are only starting clinical trials (we are basically near completion and awaiting results!)
Long story short, We will also receive expanded allowance of a patent-
their patent for gum delivery system was EXPANDED to include any of at least 85 different cannabinoid compounds found in the cannabis plant
These conditions have no known treatments and imo OWC is going after this Market!
"conditions with no currently known effective treatment including: Parkinson's disease, Alzheimer's disease/dementia, PTSD, autism, MS, spasticity, pain, RLS (restless leg syndrome), glaucoma, IBD, IBS and Crohn's disease."
AND I was reading about GW Pharma, it ties in with OWC Pharma also, good for us!
When Britain’s GW Pharmaceuticals announced that its cannabis-derived drug Epidiolex had successfully reduced seizures in children with a rare form of epilepsy, the news made headlines around the world. Investors snapped up shares of the little-known firm, effectively doubling the company’s market value overnight.
^^ What I'm saying is, once OWC announces the results of the efficacy results, expect our PPS to double if not more that day!!
I was reading about "other mmj pharma related companies" striving for FDA approval and expansion of patents.
This relates well for OWCP;
SAN DIEGO, CA--(Marketwired - November 16, 2016) - Medical Marijuana, Inc. (OTC PINK: MJNA) announced today that its major investment AXIM® Biotechnologies, Inc. (AXIM® Biotech) (AXIM), a world leader in hemp cannabinoid research and development, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 9,433,601, a patent that claims the use of all cannabinoids in cannabinoid-containing controlled-release chewing gum products.
A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from the application, filed in April 2015. This patent covers the inclusion of all cannabinoids (both natural and synthetic) in a chewing gum delivery system, including Tetrahydrocannabinol (THC), all of which may be incorporated in the Company's chewing gum products.
This new patent is an extension of AXIM® Biotech's patent for chewing gum as delivery methods for cannabidiol (Chewing Gum Compositions Comprising Cannabinoids). Prior to this new allowance, Patent 9,023,322 only claimed gum products as a delivery mechanism for cannabidiol (CBD)
"We congratulate the AXIM team on receiving this new patent, another major milestone in the Company's continued efforts to research new solutions using cannabinoid-based drugs," said Dr. Stuart Titus, CEO of Medical Marijuana, Inc.
"This patent will enable AXIM to include any of the at least 85 different cannabinoid compounds found in the cannabis plant, including CBD and THC, into its multiple cannabinoid controlled-release chewing gum products,"
<-- You see? This is only Gum, their patent for gum delivery system was EXPANDED to include any of at least 85 different cannabinoid compounds found in the cannabis plant
AXIM® Biotech developed the patents it now owns for chewing gum as a delivery method for cannabinoids into two separate products. Its CBD-only Canchew® gum is marketed and is legal to purchase wherever CBD hemp oil products are sold. AXIM® Biotech holds the exclusive rights to market and distribute CanChew® Gum globally. CanChew® is a botanical hemp-derived CBD chewing gum with a unique oral mucosal absorbance delivery system.
In addition, AXIM® will start clinical trials for its combination CBD/THC gum, MedChew® Rx, for the treatment of pain and spasticity associated with multiple sclerosis.
the estimated market size for MedChew® Rx is $4.8 billion USD. MedChew® Rx is on track to be fully registered by the EMA and FDA.
A gum delivery system with an estimated market size of $4.8 BILLION DOLLARS!
Also see they are only starting clinical trials (we are basically near completion and awaiting results!)
Long story short, We will also receive expanded allowance of a patent-
their patent for gum delivery system was EXPANDED to include any of at least 85 different cannabinoid compounds found in the cannabis plant
These conditions have no known treatments and imo OWC is going after this Market!
"conditions with no currently known effective treatment including: Parkinson's disease, Alzheimer's disease/dementia, PTSD, autism, MS, spasticity, pain, RLS (restless leg syndrome), glaucoma, IBD, IBS and Crohn's disease."
AND I was reading about GW Pharma, it ties in with OWC Pharma also, good for us!
When Britain’s GW Pharmaceuticals announced that its cannabis-derived drug Epidiolex had successfully reduced seizures in children with a rare form of epilepsy, the news made headlines around the world. Investors snapped up shares of the little-known firm, effectively doubling the company’s market value overnight.
^^ What I'm saying is, once OWC announces the results of the efficacy results, expect our PPS to double if not more that day!!
3
